Cascade Prodrug Inc is in the remaining stages of preclinical development for CPD 100Li. CPD 100Li is a prodrug designed to target and activate within the tumor microenvironment of certain cancers. Data confirms this new prodrug has demonstrated significant improvement in both the safety and efficacy endpoints. The FDA has granted CPD 100Li Orphan Drug Designation for the treatment of pancreatic cancer. Company using in-license business model.